The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

David S. Hong

Department ofInvestigational Cancer Therapeutics

Phase I Clinical Trials Program

Division of Cancer Medicine

The University of Texas MD Anderson Cancer Center

USA

[email]@mdanderson.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department ofInvestigational Cancer Therapeutics, Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, USA. 2006 - 2012
  • Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, Division of Cancer Medicine, USA. 2008 - 2009

References

  1. A phase i first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Hong, D.S., Kurzrock, R., Supko, J.G., He, X., Naing, A., Wheler, J., Lawrence, D., Eder, J.P., Meyer, C.J., Ferguson, D.A., Mier, J., Konopleva, M., Konoplev, S., Andreeff, M., Kufe, D., Lazarus, H., Shapiro, G.I., Dezube, B.J. Clin. Cancer Res. (2012) [Pubmed]
  2. Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD anderson cancer center experience. Hong, D.S., Patel, J.C., Wheler, J., Naing, A., Garrido-Laguna, I., Falchook, G., Fu, S., Tsimberidou, A.M., Kopetz, S., Win, S., Kurzrock, R. Clin. Colorectal. Cancer (2012) [Pubmed]
  3. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. Hong, D.S., Cabanillas, M.E., Wheler, J., Naing, A., Tsimberidou, A.M., Ye, L., Waguespack, S.G., Hernandez, M., El Naggar, A.K., Bidyasar, S., Wright, J., Sherman, S.I., Kurzrock, R. J. Clin. Endocrinol. Metab. (2011) [Pubmed]
  4. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Hong, D.S., Sebti, S.M., Newman, R.A., Blaskovich, M.A., Ye, L., Gagel, R.F., Moulder, S., Wheler, J.J., Naing, A., Tannir, N.M., Ng, C.S., Sherman, S.I., El Naggar, A.K., Khan, R., Trent, J., Wright, J.J., Kurzrock, R. Clin. Cancer Res. (2009) [Pubmed]
  5. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Hong, D.S., Reddy, S.B., Prieto, V.G., Wright, J.J., Tannir, N.M., Cohen, P.R., Diwan, A.H., Evans, H.L., Kurzrock, R. Arch. Dermatol (2008) [Pubmed]
  6. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Hong, D., Ye, L., Gagel, R., Chintala, L., El Naggar, A.K., Wright, J., Kurzrock, R. Mol. Cancer Ther. (2008) [Pubmed]
  7. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Hong, D.S., Abbruzzese, J.L., Bogaard, K., Lassere, Y., Fukushima, M., Mita, A., Kuwata, K., Hoff, P.M. Cancer (2006) [Pubmed]
 
WikiGenes - Universities